Murphy USA Inc. Announces Participation in Upcoming Conferences
Get Alerts MUSA Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.5%
EPS Growth %: +15.6%
Join SI Premium – FREE
EL DORADO, Ark.--(BUSINESS WIRE)-- Murphy USA Inc. (NYSE: MUSA) today announced participation in two upcoming investor conferences.
Andrew Clyde, President and CEO, will present at the Raymond James 2024 Institutional Investors Conference on Monday, March 4, 2024, at 11:35 a.m. Eastern Time (ET). The live audio webcast presentation will be available on the company’s website at https://ir.corporate.murphyusa.com.
The company will also be participating in the J.P. Morgan 2024 Global High Yield and Leveraged Finance Conference on Monday, February 26, 2024.
About Murphy USA
Murphy USA (NYSE: MUSA) is a leading retailer of gasoline and convenience merchandise with more than 1,700 stores located primarily in the Southwest, Southeast, Midwest and Northeast United States. The company and its team of nearly 15,000 employees serve an estimated two million customers each day through its network of retail gasoline and convenience stores in 27 states. The majority of Murphy USA's stores are located in close proximity to Walmart Supercenters. The company also markets gasoline and other products at standalone stores under the Murphy Express and QuickChek brands. Murphy USA ranks 182 among Fortune 500 companies.
Source: Murphy USA Inc. (NYSE: MUSA)
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222301769/en/
Investor Contact:
Christian Pikul – Vice President of Investor Relations and FP&A
[email protected]
Ash Aulds – Senior Manager of Investor Relations and FP&A
[email protected]
Source: Murphy USA Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mitsubishi Electric to Support Relief Efforts Near Nepal–China Border Following Flooding and Debris Flows
- Best Crypto Presale With a Catalyst This Week: DigiTap Sets September 30 Reveal After Raising $13M
- Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorgan, Raymond James, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share